Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry

Abstract

Use of the immunostaining results significantly improved both diagnostic accuracy and interobserver agreement. These results indicate that ovarian carcinoma type can be reliably diagnosed by pathologists from different countries, and also demonstrate that immunohistochemistry has an important role in improving diagnostic accuracy and agreement between pathologists.

Low-Grade Serous Carcinoma – The Clinical Challenge

“…In a interobserver reproducibility study of eight pathologists from European Nordic countries, consistent diagnosis of LGSC was a major issue. 26 The main differential diagnoses are against APST, endometrioid carcinoma and HGSC. In a large population based series from Denmark, only 30% of LGSC were confirmed on review but 12% of LGSC were reclassified to HGSC and 50% to APST.…”

Untitled

“…Nuclear p53 protein expression was analysed in each case, and the percentages of cells with nuclear staining were estimated as follows: complete absence, focal nuclear staining (≥1% and <70% of tumour cells), and diffuse nuclear staining (≥70% of tumour cells) [4,26,27]. Cytoplasmic and nuclear p16 staining were described as follows: expression was negative when <10% of cells were stained, if no cells were stained or if cells were stained with low intensity; focal expression when between 10% and 90% of cells were stained; and diffuse when ≥ 90% of the cells were stained [4]. Cases in which > 90% of cells were stained were considered positive, and cases in which <90% of the cells were stained were considered negative ( Figure 1).…”

“…TP53 gene mutations are present in nearly 100% of HGSOCs [3]. Diffuse and strong nuclear expression or complete lack of expression (null type) are associated more with TP53 mutations, whereas focal expression (wild type) is suggestive of the absence of mutations in HGSOC [4,15,16].…”

“…Recently, Köbel et al [4] proposed an association among WT1, p53 and p16 immunohistochemical expression in the differential diagnosis between LGSOC and HGSOC.…”

The role of topotecan in cancer ginecology treatment

“…Г и н е к о л о г и я / G y n e c o l o g y гомологичной рекомбинации HR, PTEN, ARID1A, PIK3CA характерны для эндометриоидного рака; му-тации генов BRAF или KRAS встречаются при серозном раке низкой степени злокачественности или муциноз-ных опухолях [3,4]. Такие отличия будут приводить к различному ответу на химиотерапию и определять большое число больных с рефрактерными или пла-тинорезистентными опухолями.…”